Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Dec 15, 2020 12:35pm
183 Views
Post# 32109447

RE:Checking up on Dr. J B Matson's research site ... what's new

RE:Checking up on Dr. J B Matson's research site ... what's new
MrMugsy wrote: Further investigating Dr. John B Matson for updates.
Didn't realize the work also being done in COS ... newly added ... or me just not paying attention.  Possibly the latter.
COS = Carbonyl Sulphide

More on COS ...
https://www.liebertpub.com/doi/10.1089/ars.2017.7119

---------------

WELCOME to the Matson group website. We develop new small molecules and materials for biology, medicine, and sustainability using techniques and tools from organic chemistry, polymer chemistry, and supramolecular chemistry. Our research group is interdisciplinary, using chemistry to answer biological questions, discover potential new therapeutics, explore new polymer topologies, and design sustainable materials for a broad variety of applications. Current areas of focus include:

  • New compounds and materials for gasotransmitter delivery, focused on H2S and COS
  • Photo- and biodegradable polymer synthesis
  • Peptide-based responsive materials
  • New methods for synthesis of bottlebrush polymers
  • Novel covalent nanostructures with anisotropic shapes



The part of the above link that really caught my eye ... 

"Building on these factors, this review focuses on current knowledge of biological COS formation and consumption, growing evidence that COS may play roles in sulfide transport and disease pathology, emerging chemical tools for investigating COS in biological contexts, and the potential role of COS as a new member of the gasotransmitter family."
<< Previous
Bullboard Posts
Next >>